As part of DeciBio Ventures’ strategy-heavy and supportive VC model, DeciBio Ventures is also providing Replay with ongoing strategic support.Replay’s portfolio of next-generation genomic medicine technologies aims to solve the key challenges currently limiting clinical progress, including the need for increased payload capacity and off-the-shelf cell therapies that substantially reduce cost of goods, improve production speed, volume and consistency, and expand the potential for genome engineering.Replay’s genomic medicine toolkit comprises several synergistic technology platforms, including:synHSV™ - a high payload capacity HSV vector capable of delivering up to 30x the payload of AAV.